Study overview.
MAY
This study was a prospective, 6-week, double-blind, randomized, controlled, multicenter trial in outpatients recruited in both academic and private research centers. The trial protocol was approved by local institutional review boards and was registered on ClinicalTrials.gov (NCT03012724). The study was conducted in the United States (6 sites), Israel (1 site), Canada (1 site), and Croatia (1 site), with active enrollment and treatment from May 2017 through August 2021. The trial was supported by industry (BrainsWay Ltd.). Full methods and statistical description are available in the 